The Changes of Body Fat Distribution in Obese Patients With PCOS After LSG

Shanghai 10th People's Hospital153 enrolled

Overview

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities. Abdominal fat accumulation, overweightness and obesity are frequently present in patients with PCOS . Visceral adipose tissue (VAT) plays an important role in the pathogenesis of PCOS.Therefore，this study aim to investigate the changes of body fat distribution in obese women with PCOS after laparoscopic sleeve gastrectomy (LSG), and to explore the factors that may predict the changes in body fat distribution in PCOS patients after LSG.

This study consecutively enrolled 153 patients with obesity aged 18-45 years (83 with PCOS and 70 control patients) who underwent LSG from May 2013 to September 2020 at the Department of Endocrinology, Shanghai Tenth People's Hospital, with a 12-month follow-up. Dual-energy X-ray absorptiometry (DEXA) was used to assess body fat distribution.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

153

Conditions

Polycystic Ovary Syndrome

Interventions

laparoscopic sleeve gastrectomy (LSG)PROCEDURE

Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Fmale aged 18- 45; 2. Meet Rotterdam criteria(2003); 3. body mass index (BMI)≥30 kg/m2 Exclusion Criteria: 1. Gender is male; 2. Younger than 18 years old or older than 45 years old ; 3. secondary obesity due to endocrine disorders; 4. history of malignant tumors; 5）sever hepatic and renal disease; 6\) concurrent participation in other clinical trials; 7) sever endocrine and hereditary diseases; 8) mental illnesses that rendered them unable to provide informed consent; 9) patients declining to undergo complete study testing.

Locations (1)

Department of Endocrinology, Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

VAT mass

visceral adipose tissue (VAT) mass

Time frame: 12 months

Secondary Outcomes

BMI

Body mass index (BMI) was calculated as follows: BMI = (body weight \[kg\])/(height \[m2\])

Time frame: 12 months

FBG

fasting blood-glucose in mmol/L

Time frame: 12 months

PBG

postprandial blood-glucose in mmol/L